Outcome Of Blastocyst Transfer Research Articles

Perinatal outcome of blastocyst transfer with vitrification using cryoloop: A 4-year follow-up study

To evaluate perinatal outcome of ultrarapid vitrified blastocyst transfer. Retrospective study. Private IVF clinics. One hundred eight women, who delivered 147 babies. Supernumerary blastocysts were vitrified using cryoloop method and transferred after warming. Survival rate of blastocyst after vitrification, implantation and pregnancy rates, neonatal outcome and congenital birth defects. A total of 1,129 vitrified blastocysts from 435 cycles were warmed and 967 survived (85.7%). In 413 cycles of transfer, the pregnancy, implantation, and abortion rates were 44.1%, 29.0%, and 22.0%, respectively. Of 108 deliveries, 34 (32.9%) were multiple pregnancies and 20 were preterm (18.5%). Out of 147 children born, 50.3% were male and congenital birth defects were observed in 1.4%. These results were similar with those of fresh blastocyst transfer program. The vitrification of blastocyst using cryoloop is a simple, easy, and quick method. This technique yields the same high pregnancy and implantation rates as fresh blastocyst transfer. Congenital defect rate in this study was similar to fresh blastocyst transfer, proving the method to be safe.

The outcome of blastocyst transfer following IVF v ICSI treatment cycles

ICSI treatment for male factor infertility is believed to adversely affect the blastocyst formation rate. Some studies concluded that the blastocyst formation rate is lower in ICSI than IVF cycles. Therefore, we looked at the outcome of blastocyst transfer after IVF and ICSI treatment cycles to ascertain this conclusion.

Towards a single blastocyst transfer: PGD in combination with morphology selection could be the ultimate tool

With the improvement of in vitro culture system and optimized embryo development, implantation rate has been improved dramatically. Implantation rates as high as 70% have been reported when morphologically good blastocysts were transferred (DK Gardener, 2004). However, the number of advanced maternal age patients has increased significantly, and therefore have the number of trisomies. The aim of this study was to compare the pregnancy outcomes of blastocyst transfer cases in PGD vs. non-PGD cycles. Retrospective. A total of 386 patients that underwent blastocyst transfer were included in the study. All patients had ovulation induction with gonadotropins and HCG was administered when follicle maturity was determined. Oocyte retrieval was performed 36 hours after HCG and single blastomeres were biopsied 3 days after retrieval. FISH analysis was performed for chromosomes 13, 18, 21, X and Y. 349 blastocyst transfer cases without PGD aneuploid screening (Non-PGD group, average age 34.10) while 37 cases (PGD group, average age 36.49) had blastocyst transfer after PGD-AS (PGD-Aneuploidy Screening). In the Non-PGD group, pregnancy rate was 51.3% (179/349) with the average 2.59 embryos transferred. In the PGD group, pregnancy rate was higher 64.9% (24/37) with less embryos transferred (average number of embryos transferred was 2.22) in older patient (36.49 vs. 34.10), although the difference was not significant. The embryo implantation was 50% in the PGD group compared to 47.8% in the non-PGD group with no significant difference. Table 1. Pregnancy outcomes after blastocyst transfer in PGD vs. non-PGD groups: *compared to PGD-AS group, the two-tailed Fisher’s exact test p value equals 0.1230, no significant difference. With the improvement of in vitro embryo culture system and use of sequential culture media, more embryos develop to the blastocyst stage. PGD-AS combined with morphology selection can improve single blastocyst transfer outcomes.

Clinical experience and perinatal outcome of blastocyst transfer after coculture of human embryos with human endometrial epithelial cells: a 5-year follow-up study

Objective To evaluate the reproductive and neonatal outcome of blastocyst transfer after coculture with human endometrial epithelial cells in IVF and oocyte donation. Design Retrospective study. Setting Private assisted reproductive center. Patient(s) Two hundred sixty women undergoing IVF and 469 oocyte recipients. Intervention(s) IVF or intracytoplasmic sperm injection (ICSI) and transfer of at least one blastocyst after coculture with human endometrial epithelial cells. Main outcome measure(s) Blastocyst formation rate, implantation and pregnancy rates, neonatal outcome, and congenital birth defects. Results Among patients who had transfer with their own oocytes, 1,193 of 2,349 cocultured embryos developed up to the blastocyst stage (50.8%), and pregnancy and implantation rates of 33.9% and 19.2%, respectively, were achieved. In the oocyte donation program, 1,819 blastocysts were obtained from 3,127 embryos (58.2%), with subsequent pregnancy and implantation rates of 57.0% and 31.0%, respectively. The blastocyst rate remained stable throughout the 5 years of the study, but the pregnancy and implantation rates increased dramatically. Of 139 deliveries, 57 (41.0%) were multiple pregnancies and 1 (0.7%) was a multifetal birth (four live born infants). Out of 200 children born, 59% were male, and congenital birth defects were observed in 2.5%. Conclusion(s) Coculture of human embryos with endometrial epithelial cells yields a blastocyst formation rate of 50.8% to 58.2% and encouraging implantation and pregnancy rates. This technique reduces the mean number of embryos transferred in each patient. The number of embryos implanted is more relevant to neonatal outcome than is the coculture system and blastocyst transfer used. The risk of congenital birth defects associated with this program is similar to that recorded in early ET in IVF or ICSI.

Outcome of blastocyst transfer according to availability of excess blastocysts suitable for cryopreservation

The purpose of this study was to assess the outcome of blastocyst transfer in relation to the presence or absence of excess blastocysts available for cryopreservation. The study was designed as a retrospective case series in a tertiary care private hospital. The study group consisted of 450 blastocyst stage embryo transfer cycles. In 139 cycles there were excess freezeable blastocysts (group 1), in 78 cycles there were excess but unfreezeable blastocysts (group 2), and in 233 cycles there were no excess blastocysts (group 3). A mean of three blastocysts was replaced in all groups. Treatment cycle characteristics, implantation and pregnancy rates following fresh and cryopreserved blastocyst transfer were assessed in each group. More embryos reached the blastocyst stage in group 1 and more blastocysts were of good quality. In group 1, clinical pregnancy and implantation rates (71 and 41%) were significantly higher compared with groups 2 (56 and 27%) and 3 (43 and 19%). Embryos that were selected for transfer among a cohort of good quality blastocysts yielded the highest implantation and pregnancy rates. Given a clinical pregnancy rate of 71%, an implantation rate per embryo of 41%, and a multiple pregnancy rate of 58%, serious consideration should be given to a single blastocyst transfer in these patients.

Cleavage stage versus blastocyst transfer in ICSI cycles of azoospermic couples.

Cleavage stage versus blastocyst transfer in ICSI cycles of azoospermic couples.